VFDB - anti-virulence compound 2-(7-acetyl-3-benzyl-2,4-dioxo-3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-1(2H)-yl)-N-(3-fluoro-4-methylphenyl)acetamide

Acinetobacter

Aeromonas

Anaplasma

Bacillus

Bartonella

Bordetella

Brucella

Burkholderia

Campylobacter

Chlamydia

Clostridium

Corynebacterium

Coxiella

Enterococcus

Escherichia

Francisella

Haemophilus

Helicobacter

Klebsiella

Legionella

Listeria

Mycobacterium

Mycoplasma

Neisseria

Pseudomonas

Rickettsia

Salmonella

Shigella

Staphylococcus

Streptococcus

Vibrio

Yersinia

2-(7-acetyl-3-benzyl-2,4-dioxo-3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-1(2H)-yl)-N-(3-fluoro-4-methylphenyl)acetamide

Drug details:
Molecular formula: C₂₇H₂₅FN₄O₄S

Standard name: 2-(11-acetyl-4-benzyl-3,5-dioxo-8-thia-4,6,11-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7)-dien-6-yl)-N-(3-fluoro-4-methylphenyl)acetamide

Classification: Amino acids, peptides, and analogues; Carboxylic acids and derivatives; Organic acids and derivatives; Organic compounds;

Curated SMILES: CC(=O)N1CCC2=C(C1)[SH]=C1C2C(=O)N(CC2=CC=CC=C2)C(=O)N1CC(=O)NC1=CC=C(C)C(F)=C1

Chemical structure:

Evidence for compound's anti-virulence activity:

Pseudomonas
Related VFcategory: Biofilm
Target: MvfR
Drug effect: Inhibits MvfR-regulated virulence functions.
Max phase: Preclinical (in vitro)
Publication:
Starkey M, et al., 2014. Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog 10(8):e1004321.


	Back to Top

2004-2024 NIPB, CAMS&PUMC